Johns TG - Search Results

1

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.

Endersby R, Whitehouse J, Hii H, Greenall SA, Johns TG, Gottardo NG. Endersby R, et al. Among authors: johns tg. Neoplasia. 2018 May;20(5):432-442. doi: 10.1016/j.neo.2018.02.004. Epub 2018 Mar 22. Neoplasia. 2018. PMID: 29574250 Free PMC article.

2

Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.

Perera RM, Zoncu R, Johns TG, Pypaert M, Lee FT, Mellman I, Old LJ, Toomre DK, Scott AM. Perera RM, et al. Among authors: johns tg. Neoplasia. 2007 Dec;9(12):1099-110. doi: 10.1593/neo.07721. Neoplasia. 2007. PMID: 18084617 Free PMC article.

3

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG. Pillay V, et al. Among authors: johns tg. Neoplasia. 2009 May;11(5):448-58, 2 p following 458. doi: 10.1593/neo.09230. Neoplasia. 2009. PMID: 19412429 Free PMC article.

4

Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.

Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, Murphy R, Iamele L, Scott AM, Johns TG. Greenall SA, et al. Among authors: johns tg. PLoS One. 2012;7(4):e34658. doi: 10.1371/journal.pone.0034658. Epub 2012 Apr 12. PLoS One. 2012. PMID: 22511956 Free PMC article.

5

Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth.

Nilsson UW, Johns TG, Wilmann T, Kaitu'u-Lino T, Whitehead C, Dimitriadis E, Menkhorst E, Saglam B, Gao Y, Greenall SA, Horne AW, Tong S. Nilsson UW, et al. Among authors: johns tg. Obstet Gynecol. 2013 Oct;122(4):737-744. doi: 10.1097/AOG.0b013e3182a1ba56. Obstet Gynecol. 2013. PMID: 24084529

6

Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.

Ymer SI, Greenall SA, Cvrljevic A, Cao DX, Donoghue JF, Epa VC, Scott AM, Adams TE, Johns TG. Ymer SI, et al. Among authors: johns tg. Cancers (Basel). 2011 Apr 18;3(2):2032-49. doi: 10.3390/cancers3022032. Cancers (Basel). 2011. PMID: 24212795 Free PMC article.

7

Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.

Greenall SA, Donoghue JF, Gottardo NG, Johns TG, Adams TE. Greenall SA, et al. Among authors: johns tg. Oncogene. 2015 Mar 26;34(13):1658-66. doi: 10.1038/onc.2014.106. Epub 2014 Apr 21. Oncogene. 2015. PMID: 24747966

8

EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.

Greenall SA, Donoghue JF, Van Sinderen M, Dubljevic V, Budiman S, Devlin M, Street I, Adams TE, Johns TG. Greenall SA, et al. Among authors: johns tg. Oncogene. 2015 Oct 8;34(41):5277-87. doi: 10.1038/onc.2014.448. Epub 2015 Feb 9. Oncogene. 2015. PMID: 25659577

9

Incomplete target neutralization by the anti-cancer antibody rilotumumab.

Greenall SA, Adams TE, Johns TG. Greenall SA, et al. Among authors: johns tg. MAbs. 2016;8(2):246-52. doi: 10.1080/19420862.2015.1122149. MAbs. 2016. PMID: 26750997 Free PMC article.

10

EGFRvIII: the promiscuous mutation.

Greenall SA, Johns TG. Greenall SA, et al. Among authors: johns tg. Cell Death Discov. 2016 Jul 4;2:16049. doi: 10.1038/cddiscovery.2016.49. eCollection 2016. Cell Death Discov. 2016. PMID: 27551537 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters